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Context: SUV measurement with 111In-IT SPECT/CT was a
very useful predictor for the therapeutic effect and grade of
post-treatment neutropenia due to 90Y-IT therapy. Background:
90Y-labelled Ibritumomab tiuxetan (90Y-IT) therapy is one of
radioimmunotherapy for indolent B-cell lymphoma. 111In-IT
single photon emission computed tomography/computed tomog-
raphy (SPECT/CT) is used for imaging examination to exclude
ineligible cases for 90Y-IT administration, which is actual
therapeutic drug. Objective: To determine whether there is rela-
tionship between the tumor and bone marrow 111In-IT uptake
and the treatment effect and post-treatment cytopenia of 90Y-IT
therapy. Design: Retrospective study, from January 2017 to
March 2019. Patients: Consecutive patients treated with 90Y-IT
therapy. Results: There were 13 cases (7 men and 6 women),
including 12 cases who underwent 111In-IT SPECT/CT. Median
age was 68 (range, 59-89) years old. 11 of 13 cases were diagnosed
as follicular lymphoma. Median number of previous regimens was
1 (1-3). Median level of soluble IL-2 receptor before 90Y-IT
therapy was 792 (281-1550) U/ml. Median maximum
SUV (SUVmax) in the tumor was 5.28 (0-22.28). Median mean
SUV (SUVmean) in the bone marrow was 2.69 (1.33-3.39).
After 90Y-IT therapy, there were 4 cases with complete remission
(CR), 4 cases with partial remission (PR), 2 cases with stable
disease, and 1 case with progressive disease, respectively. The other
cases have not been evaluated at this time. Median number of the
lowest neutrophil and platelet count after 90Y-IT therapy were
546.5 (147-2230)/mL and 5.3 (1.7-9.1)  104/mL, respectively. In
patients with CR and CR/PR achievement, the tumor
SUVmax was signiﬁcantly lower than the others (P<0.05,
P<0.05). The cutoff values that predict CR and CR/PR using
ROC analysis were 5.98 (AUC 0.893) and 8.69 (AUC 0.964),
respectively. In patients whose neutrophils decreased less than
500/uL after 90Y-IT therapy, the bone marrow SUVmean was
signiﬁcantly higher (P<0.05) and the cutoff value was 2.45 (AUC
0.857). Conclusions: SUV measurement with 111In-IT SPECT/
CT was a very useful predictor for the therapeutic effect and grade
of post-treatment neutropenia due to 90Y-IT therapy. Keywords:
ibritumomab tiuxetan, SPECT/CT, IBCL, indolent B-cell
lymphoma- Clinical Lymphoma, Myeloma & Leukemia September 2019IBCL-064
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Context: Duvelisib, a ﬁrst-in-class oral dual PI3-kinase-d,g in-
hibitor, is approved for the treatment of R/R CLL/SLL after2 prior
therapies and for follicular lymphoma (FL) after 2 prior systemic
therapies. DYNAMO, a phase 2 trial that evaluated the safety and
efﬁcacy of duvelisib monotherapy in iNHL, including patients with
marginal zone lymphoma (MZL). Patients were double refractory to
rituximab-based therapy and chemotherapy or radioimmunotherapy.
Objective: To characterize efﬁcacy and safety of duvelisib for patients
with MZL from DYNAMO.Design: DYNAMO was an open-label,
single-arm trial in which patients received duvelisib 25 mg BID until
disease progression or unacceptable toxicity. Primary endpoint was
overall response rate (ORR) as assessed by independent review
committee (IRC) per revised International Working Group criteria.
Secondary endpoints included duration of response, progression-free
survival (PFS) and safety. Results: Of the 129 patients in DY-
NAMO, 18 were of MZL histology, including 50% extranodal,
22.2% nodal, and 27.8% splenic subtypes. Median number of prior
regimens was 2 (range, 1-8); 67% (n¼12) were refractory to 2
regimens. The ORR per IRC was 39% (95% CI, 17.3%-64.3%),
including 1 CR (ORR by subtype: 0% extranodal, 75% nodal, 80%
splenic). Median time to response was 3.7 months. As of the data
cutoff (18May2018) median duration of response had not been
reached. The median PFS by IRC was 15.5 months (95% CI, 3.6-
27.8 months). Adverse events (AEs) were mostly grade 1/2, the most
common grade 3 AEs were neutropenia (28%) and diarrhea
(17%). 33% of patients discontinued duvelisib due to AE(s),
including 3 who were in PR at discontinuation. Follow-up imaging is
not available for 1 patient, but the other 2 had sustained responses of
Abstracts>1 year as of most recent imaging after treatment discontinuation.
There was 1 grade 5 non-PD related AE of pancolitis (classiﬁed as
potentially related to duvelisib). Conclusions: Duvelisib demon-
strated clinically meaningful antitumor activity in patients with
MZL. Duvelisib had a manageable safety proﬁle, consistent with
previous reports. These preliminary ﬁndings suggest that duvelisib
represents a promising treatment option that warrants further
investigation in patients with double-refractory MZL where limited
treatment options exist. Keywords: marginal zone lymphoma, PI3K,
duvelisib, IBCL, indolent B-cell lymphomaIBCL-164
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Context: Idelalisib (Zydelig, IDELA) is a PI3K d inhibitor
approved for treatment of relapsed or refractory (R/R) follicular
lymphoma and in combination with anti-CD20 for R/R chronic
lymphocytic leukemia (CLL). Objective: To evaluate the impact of
IDELA treatment interruption on duration of IDELA therapy
(DoT), progression-free survival (PFS) and overall survival (OS) in
patients with R/R indolent non-Hodgkin’s lymphoma (iNHL) and
R/R CLL. Design: Retrospective analysis using data collected from
patients with R/R iNHL treated with IDELA (Gopal et al., N. Engl.
J. Med., 2014) or from patients with R/R CLL treated with IDELA
+ anti-CD20 (Furman et al., N. Engl. J. Med., 2014 and Jones et al.,
Lancet Haematol., 2017). Setting: Multi-site clinical trials.
Interventions: IDELA interruption for at least one treatment day
due to an AE. Main Outcomes: Comparison of IDELA DoT, PFS
and OS of patients stratiﬁed by number of interruptions (0, 1 or2)
and by percentage of time off therapy (0, 8% and >8%). Results:
Among iNHL patients, 62 of 125 (49.6%) interrupted therapy
(31.2% with 1 and 18.4% with 2 interruptions) and among CLL
patients, 157 of 283 (55.5%) interrupted therapy (27.2% with 1 and
28.3% with 2 interruptions). The most common AEs (any grade)
leading to interruption were diarrhea, cytopenias/febrile neutropenia,
hepatic toxicity and pneumonia. Patients without treatment inter-
ruption had a shorter DoT than patients with either 1 or 2 in-
terruptions. Patients who experienced 1 or 2 treatment
interruptions achieved a longer PFS and OS than patients with no
interruption. To account for differences in DoT across the inter-
ruption groups, PFS and OS were compared based on percentage of
time off therapy (8% time off therapy and >8% time off therapy).Patients who interrupted with time off therapy 8%, but not >8%,
had improved PFS and OS compared to patients who did not
interrupt. Conclusions: In these clinical studies, both iNHL and
CLL patients who interrupted therapy for a limited period had
longer DoT and achieved longer PFS and OS than patients who did
not interrupt. The impact of intermittent IDELA therapy on clinical
outcomes should be conﬁrmed with prospective clinical studies.
Keywords: idelalisib, follicular lymphoma, CLL, intermittent ther-
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Objective: We realized an update of the French national retro-
spective cohort of hairy cell leukemias (HCL) after 10 years of
follow up, focusing on second cancers. Design: Data were collected
up to June 2018 thanks to a questionnaire sent to the members of
the Société Française d’Hématologie, and centralized in the cohort
database. To evaluate the excess of cancers in our cohort in com-
parison with the French general population, we calculated the
standardized incidence ratio (SIR). Results: 279 patients (pts) from
19 centers were included (median age 59 years old (29-88)). 21%
had an infectious disease at diagnosis, 23% had a familial history of
cancer and 11% a personal history of cancer. The median follow upClinical Lymphoma, Myeloma & Leukemia September 2019 - S313
